DNAPrint Genomics Net Worth
DNAPrint Genomics Net Worth Breakdown | DNAG |
DNAPrint Genomics Net Worth Analysis
DNAPrint Genomics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including DNAPrint Genomics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of DNAPrint Genomics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform DNAPrint Genomics' net worth analysis. One common approach is to calculate DNAPrint Genomics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares DNAPrint Genomics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing DNAPrint Genomics' net worth. This approach calculates the present value of DNAPrint Genomics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of DNAPrint Genomics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate DNAPrint Genomics' net worth. This involves comparing DNAPrint Genomics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into DNAPrint Genomics' net worth relative to its peers.
Enterprise Value |
|
To determine if DNAPrint Genomics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding DNAPrint Genomics' net worth research are outlined below:
| DNAPrint Genomics generated a negative expected return over the last 90 days | |
| DNAPrint Genomics has some characteristics of a very speculative penny stock | |
| DNAPrint Genomics has a very high chance of going through financial distress in the upcoming years | |
| DNAPrint Genomics currently holds 240 K in liabilities. DNAPrint Genomics has a current ratio of 0.17, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about DNAPrint Genomics' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 2.43 M. Net Loss for the year was (12.35 M) with profit before overhead, payroll, taxes, and interest of 446.37 K. | |
| DNAPrint Genomics currently holds about 134.35 K in cash with (5.78 M) of positive cash flow from operations. | |
| DNAPrint Genomics has a frail financial position based on the latest SEC disclosures |
Follow DNAPrint Genomics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 386.76 K.Market Cap |
|
Project DNAPrint Genomics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.11) | (1.16) | |
| Return On Capital Employed | 2.28 | 2.13 | |
| Return On Assets | (1.08) | (1.14) | |
| Return On Equity | 3.83 | 4.02 |
When accessing DNAPrint Genomics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures DNAPrint Genomics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of DNAPrint Genomics' profitability and make more informed investment decisions.
Evaluate DNAPrint Genomics' management efficiency
DNAPrint Genomics has return on total asset (ROA) of (1.05) % which means that it has lost $1.05 on every $100 spent on assets. This is way below average. DNAPrint Genomics' management efficiency ratios could be used to measure how well DNAPrint Genomics manages its routine affairs as well as how well it operates its assets and liabilities. The DNAPrint Genomics' current Return On Equity is estimated to increase to 4.02, while Return On Tangible Assets are projected to decrease to (1.16). At this time, DNAPrint Genomics' Other Current Assets are most likely to increase significantly in the upcoming years. The DNAPrint Genomics' current Total Current Assets is estimated to increase to about 10.6 M, while Return On Tangible Assets are projected to decrease to (1.16).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.01) | (0.01) | |
| Tangible Book Value Per Share | (0.01) | (0.01) | |
| Enterprise Value Over EBITDA | (1.01) | (1.06) | |
| Price Book Value Ratio | (1.03) | (0.98) | |
| Enterprise Value Multiple | (1.01) | (1.06) | |
| Price Fair Value | (1.03) | (0.98) | |
| Enterprise Value | 11.5 M | 14.8 M |
Evaluating the management effectiveness of DNAPrint Genomics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The DNAPrint Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
DNAPrint Genomics Earnings per Share Projection vs Actual
DNAPrint Genomics Corporate Management
| FRCPC MD | Ex Officer | Profile | |
| Hector Ruiz | Ex Officer | Profile | |
| Zach Gaskin | Ex Officer | Profile | |
| Shannon Boyd | Ex Officer | Profile | |
| Jatin Patel | Ex Officer | Profile | |
| Lisa Herren | Ex Officer | Profile | |
| Pauline Gula | Ex Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DNAPrint Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in DNAPrint Stock please use our How to Invest in DNAPrint Genomics guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DNAPrint Genomics. If investors know DNAPrint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DNAPrint Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of DNAPrint Genomics is measured differently than its book value, which is the value of DNAPrint that is recorded on the company's balance sheet. Investors also form their own opinion of DNAPrint Genomics' value that differs from its market value or its book value, called intrinsic value, which is DNAPrint Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DNAPrint Genomics' market value can be influenced by many factors that don't directly affect DNAPrint Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DNAPrint Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DNAPrint Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DNAPrint Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.